Published in Proc Natl Acad Sci U S A on August 22, 2005
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol (2006) 4.24
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev (2005) 3.18
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A (2009) 1.83
Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog (2014) 1.69
Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J Virol (2006) 1.59
Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses (2012) 1.55
Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol (2008) 1.47
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol (2010) 1.44
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol (2011) 1.44
A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol (2010) 1.40
Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J Virol (2006) 1.34
Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol (2013) 1.21
Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One (2013) 1.19
Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses (2012) 1.18
The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells. J Virol (2006) 1.17
Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. J Virol (2008) 1.16
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells. J Virol (2011) 1.14
Protease-mediated entry via the endosome of human coronavirus 229E. J Virol (2008) 1.09
Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med (2015) 1.06
Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis. J Virol (2009) 1.05
Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One (2009) 1.05
Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol (2012) 1.04
Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol (2014) 1.02
Suppression of coronavirus replication by inhibition of the MEK signaling pathway. J Virol (2006) 1.01
Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses. PLoS One (2013) 0.99
Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res (2013) 0.98
Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. J Virol (2007) 0.92
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res (2014) 0.92
Reversible unfolding of the severe acute respiratory syndrome coronavirus main protease in guanidinium chloride. Biophys J (2006) 0.90
Elastase-mediated activation of the severe acute respiratory syndrome coronavirus spike protein at discrete sites within the S2 domain. J Biol Chem (2010) 0.90
Autographa californica multicapsid nucleopolyhedrovirus efficiently infects Sf9 cells and transduces mammalian cells via direct fusion with the plasma membrane at low pH. J Virol (2010) 0.88
DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry. J Virol (2014) 0.88
Identification and characterization of a proteolytically primed form of the murine coronavirus spike proteins after fusion with the target cell. J Virol (2014) 0.86
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol (2013) 0.86
Receptor-independent infection of murine coronavirus: analysis by spinoculation. J Virol (2006) 0.81
Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol (2016) 0.80
Fusion of Enveloped Viruses in Endosomes. Traffic (2016) 0.80
Amino acid substitutions in the s2 region enhance severe acute respiratory syndrome coronavirus infectivity in rat angiotensin-converting enzyme 2-expressing cells. J Virol (2007) 0.79
Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design. Protein Sci (2014) 0.78
Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry. J Virol (2016) 0.77
Incorporation of spike and membrane glycoproteins into coronavirus virions. Viruses (2015) 0.76
Neurovirulent Murine Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry and Cell-Cell Fusion. J Virol (2017) 0.75
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (2003) 13.79
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
Activation of influenza A viruses by trypsin treatment. Virology (1975) 8.07
The molecular biology of coronaviruses. Adv Virus Res (1997) 6.62
Lung pathology of fatal severe acute respiratory syndrome. Lancet (2003) 5.02
Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology (1976) 4.85
Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science (2004) 4.18
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A (2004) 3.03
Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology (2003) 2.36
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol (2004) 2.21
Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J Virol (1991) 2.16
Role of Staphylococcus protease in the development of influenza pneumonia. Nature (1987) 1.96
The role of neutrophil elastase in acute lung injury. Eur J Pharmacol (2002) 1.62
Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol (2004) 1.39
Proliferative growth of SARS coronavirus in Vero E6 cells. J Gen Virol (2003) 1.24
Co-infection of Staphylococcus aureus or Haemophilus paragallinarum exacerbates H9N2 influenza A virus infection in chickens. Arch Virol (2004) 1.18
Trypsin action on the growth of Sendai virus in tissue culture cells. IV. Evidence for activation of sendai virus by cleavage of a glycoprotein. J Virol (1976) 0.94
Impaired entry of soluble receptor-resistant mutants of mouse hepatitis virus into cells expressing MHVR2 receptor. Virology (2000) 0.93
Digestive system manifestations in patients with severe acute respiratory syndrome. Chin Med J (Engl) (2003) 0.86
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis (2013) 4.92
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
Characterization of H7N9 influenza A viruses isolated from humans. Nature (2013) 3.71
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis (2002) 2.38
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med (2004) 2.31
Pause on avian flu transmission research. Science (2012) 2.24
Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer (2004) 2.04
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. Vaccine (2006) 1.61
Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis (2007) 1.56
Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer. PLoS One (2010) 1.56
Reston Ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis (2011) 1.54
Species-independent detection of RNA virus by representational difference analysis using non-ribosomal hexanucleotides for reverse transcription. Nucleic Acids Res (2005) 1.51
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol (2010) 1.44
Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem (2008) 1.44
The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine (2005) 1.42
Receptor-induced conformational changes of murine coronavirus spike protein. J Virol (2002) 1.39
LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol (2006) 1.38
Immunofluorescence technique using HeLa cells expressing recombinant nucleoprotein for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Clin Microbiol (2002) 1.37
Novel DNA virus isolated from samples showing endothelial cell necrosis in the Japanese eel, Anguilla japonica. Virology (2011) 1.37
Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Clin Microbiol (2002) 1.35
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther (2005) 1.33
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses (2011) 1.32
Bat coronaviruses and experimental infection of bats, the Philippines. Emerg Infect Dis (2010) 1.32
Rapid diagnosis of H5N1 avian influenza virus infection by newly developed influenza H5 hemagglutinin gene-specific loop-mediated isothermal amplification method. J Virol Methods (2007) 1.29
Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan. PLoS One (2010) 1.28
Rapid determination of viral RNA sequences in mosquitoes collected in the field. J Virol Methods (2007) 1.27
Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin Vaccine Immunol (2006) 1.26
Isolation of novel adenovirus from fruit bat (Pteropus dasymallus yayeyamae). Emerg Infect Dis (2008) 1.26
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci (2009) 1.22
Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci (2004) 1.21
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg Infect Dis (2010) 1.21
Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. J Virol (2008) 1.16
Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. Clin Chem (2004) 1.16
Rapid genome sequencing of RNA viruses. Emerg Infect Dis (2007) 1.15
Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation. J Virol (2004) 1.15
Lethal canine distemper virus outbreak in cynomolgus monkeys in Japan in 2008. J Virol (2012) 1.14
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells. J Virol (2011) 1.14
Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer. J Epidemiol (2008) 1.14
Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A (2005) 1.13
Association of the nucleocapsid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. Virus Res (2003) 1.13
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg Infect Dis (2011) 1.12
Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol (2008) 1.12
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol (2004) 1.10
Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA (2009) 1.10
Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol (2005) 1.09
The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination. Jpn J Infect Dis (2010) 1.09
Importance of the anti-interferon capacity of Sendai virus C protein for pathogenicity in mice. J Virol (2007) 1.09
Protease-mediated entry via the endosome of human coronavirus 229E. J Virol (2008) 1.09
Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology (2002) 1.08
Detection of bat coronaviruses from Miniopterus fuliginosus in Japan. Virus Genes (2011) 1.08
Divergent ancestral lineages of newfound hantaviruses harbored by phylogenetically related crocidurine shrew species in Korea. Virology (2012) 1.08
Transmission studies resume for avian flu. Science (2013) 1.07
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J (2010) 1.06
The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses. J Virol (2014) 1.05
Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect (2007) 1.05
Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis. J Virol (2009) 1.05
Wild-type measles virus induces large syncytium formation in primary human small airway epithelial cells by a SLAM(CD150)-independent mechanism. Virus Res (2003) 1.05
Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol (2011) 1.05
Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol (2012) 1.04
Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. Acta Neuropathol (2004) 1.02
The intracellular association of the nucleocapsid protein (NP) of hantaan virus (HTNV) with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9). Virology (2003) 1.02
Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells. Biochem Biophys Res Commun (2004) 1.01
Novel betaherpesvirus in bats. Emerg Infect Dis (2010) 1.01
Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J Virol (2006) 1.01
Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene. J Virol Methods (2010) 1.01
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem (2010) 1.01
Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol (2005) 1.00
Development of an immunofluorescence method for the detection of antibodies to Ebola virus subtype Reston by the use of recombinant nucleoprotein-expressing HeLa cells. Microbiol Immunol (2002) 1.00
Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. Western Pac Surveill Response J (2013) 0.99
The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J Virol (2012) 0.99
Ligation-mediated amplification for effective rapid determination of viral RNA sequences (RDV). J Clin Virol (2008) 0.98
The amino-terminal half of Sendai virus C protein is not responsible for either counteracting the antiviral action of interferons or down-regulating viral RNA synthesis. J Virol (2002) 0.98
N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein. J Virol (2004) 0.97
Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells. Virology (2004) 0.97
Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. J Gen Virol (2009) 0.96
Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis (2009) 0.96
Novel bat-borne hantavirus, Vietnam. Emerg Infect Dis (2013) 0.95
Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. Life Sci (2003) 0.95
Multilocus sequence typing of Cryptococcus neoformans in non-HIV associated cryptococcosis in Nagasaki, Japan. Med Mycol (2012) 0.95
Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J Med Virol (2004) 0.95
One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods (2010) 0.95
Analysis of linear B-cell epitopes of the nucleoprotein of ebola virus that distinguish ebola virus subtypes. Clin Diagn Lab Immunol (2003) 0.94
Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. Bioorg Med Chem (2010) 0.94
Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J Virol (2009) 0.93
Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis (2009) 0.93